Welcome to our dedicated page for Biovie SEC filings (Ticker: BIVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioVie Inc maintains regulatory compliance through periodic filings with the Securities and Exchange Commission that provide detailed information about the company's clinical development activities, financial condition, and business operations. These documents offer investors comprehensive insights into the status of drug development programs and corporate strategic direction.
Quarterly reports provide updates on clinical trial progress, including patient enrollment status, trial design modifications, and preliminary or final data from completed studies. Financial sections detail research and development expenditures allocated to each program, providing visibility into resource allocation and development priorities. Management discussion sections analyze clinical developments, regulatory interactions, and upcoming milestones that may impact the business.
Annual reports offer extensive discussion of drug development programs, including detailed descriptions of drug mechanisms, clinical trial designs, and regulatory strategies. Risk factor sections outline challenges inherent in clinical-stage biopharmaceutical development, including clinical trial uncertainties, regulatory approval risks, and commercialization challenges. These filings also provide information about intellectual property portfolios, patent expirations, and competitive landscape assessments.
Current reports disclose material events such as clinical trial results, regulatory communications, strategic partnerships, financing transactions, and significant corporate developments. These timely disclosures keep investors informed of developments between quarterly reporting periods.
Proxy statements provide information about corporate governance, board composition, executive compensation structures, and matters requiring shareholder approval. Registration statements and prospectuses detail securities offerings that fund clinical development activities.
Reviewing SEC filings enables investors to track the evolution of clinical programs, understand financial runway for completing development activities, and assess management's strategic priorities. The filings provide detailed scientific and regulatory context often not available in press releases or other corporate communications.
BioVie Inc. (BIVI) has filed a Form S-8 registration statement for its 2019 Omnibus Equity Incentive Plan, which has been amended and restated through November 10, 2025. This filing allows the company to register shares that may be issued to employees, directors and other service providers as equity-based compensation under the updated plan. The document also outlines Nevada law provisions that protect and indemnify directors and officers, and notes that BioVie may advance expenses and purchase insurance for them. The filing is signed by Chief Executive Officer Cuong Do and other senior leaders, confirming their authorization to submit amendments and related documents as needed.
BioVie Inc. reported that stockholders approved an amendment and restatement of its 2019 Omnibus Equity Incentive Plan, effective November 10, 2025. The revised plan increases the number of shares of common stock authorized for issuance under the plan to 3,100,000 shares.
The plan is intended to help attract, retain, and incentivize employees, directors, and consultants, and to align their interests with stockholders. The full amended plan is incorporated by reference from the company’s September 25, 2025 definitive proxy statement.
BioVie Inc. reported results from its 2025 annual meeting of stockholders. On the September 22, 2025 record date, 7,535,080 shares were outstanding, and 3,417,857 shares were present for quorum. Stockholders elected all six director nominees to one‑year terms; each nominee received over 1.51 million "For" votes, with 1,864,509 broker non‑votes recorded on each director item.
Stockholders ratified EisnerAmper LLP as independent auditor for the fiscal year ending June 30, 2026 with 3,245,049 For, 141,868 Against, and 30,940 Abstain. They also approved an amendment and restatement of the 2019 Omnibus Equity Incentive Plan to increase the number of shares authorized for issuance to 3,100,000 (votes: 1,340,062 For, 207,794 Against, 5,492 Abstain, and 1,864,509 broker non‑votes).
BioVie Inc. filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $5.1 million, driven by operating expenses of $5.3 million (R&D $2.9 million; G&A $2.3 million). Other income, net, was $0.2 million mainly from interest income.
Cash and cash equivalents rose to $25.0 million from $17.5 million at June 30, 2025, supported by net proceeds of approximately $10.5 million from an August 2025 underwritten offering of units and pre-funded units, each including warrants exercisable at $2.50. Net cash used in operations was $3.0 million.
The company advanced its clinical programs: a Phase 2b study in Parkinson’s disease commenced in April 2025, and the DOD-funded Long COVID Phase 2 study continued, with $336,000 in grant reimbursements recognized this quarter. BioVie disclosed “substantial doubt” about its ability to continue as a going concern, noting dependence on additional financing. A 1-for-10 reverse stock split became effective July 7, 2025. Shares outstanding were 7,540,316 as of November 7, 2025.
BioVie Inc. (BIVI) filed a Form 3, the initial statement of beneficial ownership for a board member. The reporting person is a Director, and the filing states that no securities are beneficially owned as of the event date 07/17/2025. The form indicates it was filed by one reporting person. This is a routine ownership disclosure that establishes the insider’s baseline holdings at the time of becoming subject to reporting.
BioVie Inc. (BIVI) disclosed a Form 3 filed by a director, indicating no securities are beneficially owned by the reporting person. The filing identifies the relationship as Director and notes the event date as 07/17/2025. The form was filed by one reporting person.
BioVie Inc. solicits shareholder votes at its virtual annual meeting and presents director nominees, auditor ratification and an amendment to increase shares available under its 2019 equity plan to 3,100,000 shares. The proxy names the board slate including Cuong Do (President & CEO) and committee chairs for audit, compensation and governance. Compensation tables show named executive officer pay components: for example, the CEO's total compensation entries include cash and equity components (reported totals such as $777,082 for one year and $420,621 for another row). Director and NEO equity holdings and outstanding option/RSU schedules are disclosed, including a listed beneficial ownership aggregate of 65,312 shares (0.9%) for listed insiders. Audit fees paid to the auditor are disclosed (audit-related fees shown as $99,750 and tax fees $26,250).
BioVie, Inc. (BIVI) is a development-stage biopharmaceutical company with no products approved for commercial sale and no revenues expected in the foreseeable future. The company reported approximately $17.5 million in cash and cash equivalents, stockholders' equity of about $19.0 million, and an accumulated deficit of approximately $352.1 million. For the year, reported net losses included $(17,911,585) and $(33,006,956) as referenced in the statements, with net loss per common share of $(12.12) for the most recent period on a weighted average of 1,477,372 shares. BioVie continues preclinical and clinical development activities, holds multiple issued and pending patents and patent applications, and lists significant operational risks including dependence on third-party contractors, need for additional capital, litigation, manufacturing and regulatory hurdles, and potential volatility and dilution from equity financings. Recent equity raises and warrant offerings are described, and management discloses lease, debt, and fair-value measurement items that affected financing costs and interest expense.
FAQ
What is the current stock price of Biovie (BIVI)?
What is the market cap of Biovie (BIVI)?
